Development of Antibacterial, Antifungal and Antituberculosis Drugs

The research of the “Development of Antibacterial, Antifungal and Antituberculosis Drugs” group is mainly focused on pharmaceutical (medicinal) chemistry of the compounds with potential antimicrobial activities. Based on current knowledge in this particular field, we design and synthesize selected compounds of various chemical structures and study their structure-activity relationships with respect to antimicrobial activity, cytotoxicity and selectivity. In cooperation with several research groups, we study the mode of action of our compounds. The majority of the studied compounds with antimicrobial activities belong to the group of salicylanilides, nitrogen heterocycles and nitro group-containing compounds.

Second line of our research is focused on the structure-activity relationships of dexrazoxane, the only approved drug capable of preventing anthracycline-induced cardiotoxicity both in experimental models and clinical practice. As a part of this research, we also study the acylhydrazone-type and thiosemicarbazone-type iron chelators.

Additionally, we investigate also potential inhibitors of acetylcholinesterase and butyrylcholine esterase, especially those based on carbamate moiety and phenolic derivatives.

We are open to collaborations in those areas of research; feel free to contact us.

News

  •  Ph.D. positions available (both in Czech and English language; starting in October 2019, applications are accepted until April 30, 2019)

Topics:

1. Synthesis of nitro-substituted heteroaromates as potential antitubercular agents and study of their structure-activity relationships
2. Synthesis of analogues of clinically used cardioprotective drug dexrazoxane and study of their structure-activity relationships

  • December 2018 - Svenox Pharmaceutical LLC bought the property rights to our

    application for invention No. PV 2018 – 664 entitled "Substituted 1,2,4-oxadiazole, its use and pharmaceutical preparation containing the same"

  • November 2018 - Jaroslav was awarded by the Alfred Bader’s Prize in bioorganic and bioinorganic chemistry

  • June 2017 - Jaroslav and Galina attended the Gordon Research Conference: Tuberculosis Drug Discovery & Development (Renaissance Tuscany Il Ciocco, Lucca (Barga), Italy)

 

  • May 2017 - Jan Kubeš won the first prize of ZENTIVA company in Chemistry at the 16th International Pharmacy Student Research Conference

      

  • April 2017 Jan Kubeš (on the left) won the first prize in Chemistry at the 25th Pharmacy Student Research Conference

© Charles University, Faculty of Pharmacy in Hradec Králové, Akademika Heyrovského 1203, 500 05 Hradec Králové, Czech Republic
Website information | Powered by Kentico